Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 18/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15278119 | 0.85 | FOLH1 (1.00) | FOLH1 | |
| SCHEMBL23894146 | 0.85 | FOLH1 (0.60) | FOLH1 | |
| SCHEMBL17849920 | 0.85 | FOLH1 (1.00) | FOLH1 | |
| SCHEMBL19352030 | 0.84 | FOLH1 (0.73) | FOLH1SMN1; SMN2 | |
| SCHEMBL1200060 | 0.84 | FOLH1 (0.71) | FOLH1SMN1; SMN2ADRA1A | |
| SCHEMBL2735591 | 0.84 | FOLH1 (0.71) | FOLH1SMN1; SMN2ADRA1A | |
| SCHEMBL16393150 | 0.84 | FOLH1 (0.71) | FOLH1SMN1; SMN2ADRA1A | |
| SCHEMBL20018480 | 0.82 | FOLH1 (0.78) | FOLH1 | |
| SCHEMBL20018424 | 0.82 | FOLH1 (0.83) | FOLH1 | |
| SCHEMBL19360024 | 0.82 | FOLH1 (0.83) | FOLH1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10201624-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10201624-B2 | Triazine based radiopharmaceuticals and radioimaging agents | PSMA5, PSMA2, PSMA1 | FOLH1 7/4885SMN1; SMN2 3793/4885ADRA1A 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.